Cancer trial aimed at clearing HPV after treatment pulled before starting
NCT ID NCT05363709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed for people with HPV-positive oropharyngeal cancer who still had signs of the virus in their blood after completing standard treatment. Researchers planned to give an immunotherapy drug called BALSTILIMAB to see if it could clear the virus and improve long-term survival. However, the trial was withdrawn before enrolling any participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can less radiation be safer for throat cancer?
- Could Self-Sampling revolutionize cervical cancer screening?
- Texting parents could be key to curbing HPV-Related cancers
- Pocket-sized HIV test could bring same-day diagnosis to community clinics
- Can anal cancer treatment spare sexual well-being? a study tracks the toll over two years.
- Can a simple swab predict who needs less radiation?